Clinical Trials · NCT00044668
Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 155
- Start date
- Aug 2002
- Locations
- 3 sites, Hungary
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24, Week 52, and to each intermediate visit